Ezetimibe Tablet
NDC Package 69238-1154-1
Package Information
Ezetimibe tablets are indicated:In combination with a statin, or alone when additional low-density lipoprotein cholesterol (LDL-C) lowering therapy is not possible, as an adjunct to diet to reduce elevated LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH).In combination with a statin as an adjunct to diet to reduce elevated LDL-C in pediatric patients 10 years of age and older with HeFH.In combination with fenofibrate as an adjunct to diet to reduce elevated LDL-C in adults with mixed hyperlipidemia.In combination with a statin and other LDL-C lowering therapies, to reduce elevated LDL-C levels in adults and in pediatric patients 10 years of age and older with homozygous familial hypercholesterolemia (HoFH).As an adjunct to diet for the reduction of elevated sitosterol and campesterol levels in adults and in pediatric patients 9 years of age and older with homozygous familial sitosterolemia.When ezetimibe tablets are used in combination with a statin, fenofibrate, or other LDL-C lowering therapies, refer to the Prescribing Information of these products for information on the safe and effective use. This formulation utilizes a tablet delivery system. Marketed by Amneal Pharmaceuticals Ny Llc, this product is identified by NDC 69238-1154 and is authorized under FDA application ANDA208803.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 69238 - Amneal Pharmaceuticals Ny Llc
- 69238-1154 - Ezetimibe
- 69238-1154-1 - 1000 TABLET in 1 BOTTLE
- 69238-1154 - Ezetimibe
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (69238-1154). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 69238-1154-1 identifies a specific commercial package of 1000 tablet in 1 bottle of Ezetimibe, a human prescription drug labeled by Amneal Pharmaceuticals Ny Llc. This tablet is formulated for oral use and contains ezetimibe as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Amneal Pharmaceuticals Ny Llc on June 12, 2017. The current certification is valid through December 31, 2027.
How is this Amneal Pharmaceuticals Ny Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 69238115401. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.